

Massimo Iavarone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8853361/publications.pdf>

Version: 2024-02-01

280
papers

7,322
citations

76326

40
h-index

62596

80
g-index

286
all docs

286
docs citations

286
times ranked

8909
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. <i>Journal of Hepatology</i> , 2022, 76, 302-310.	3.7	48
2	Prothrombin induced by vitamin K absence or antagonist and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 350-359.	3.7	11
3	Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second-line clinical trials. <i>Liver International</i> , 2022, 42, 458-467.	3.9	6
4	Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5). <i>Cancers</i> , 2022, 14, 336.	3.7	5
5	An Unprecedented Challenge: The North Italian Gastroenterologist Response to COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 109.	2.4	0
6	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	3.9	11
7	Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19. <i>Gut</i> , 2021, 70, 1798-1799.	12.1	1
8	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 370-379.	7.7	31
9	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	4.9	36
10	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2021, 41, 2997-3008.	3.9	18
11	The Interplay between Gut Microbiota and the Immune System in Liver Transplant Recipients and Its Role in Infections. <i>Infection and Immunity</i> , 2021, 89, e0037621.	2.2	13
12	Congenital Hepatic Fibrosis as a Cause of Recurrent Cholangitis: A Case Report and Review of the Literature. <i>Livers</i> , 2021, 1, 132-137.	1.9	2
13	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021, 27, 1767-1778.	2.4	19
14	Reshape and secure HCC managing during COVID-19 pandemic: A single centre analysis of four periods in 2020 versus 2019. <i>Liver International</i> , 2021, 41, 3028-3032.	3.9	5
15	Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. <i>Cancers</i> , 2021, 13, 5797.	3.7	13
16	Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. <i>ESMO Open</i> , 2021, 6, 100330.	4.5	25
17	Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. <i>Cancer Management and Research</i> , 2021, Volume 13, 9379-9389.	1.9	31
18	Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation. <i>Transplantation</i> , 2020, 104, 568-574.	1.0	40

#	ARTICLE	IF	CITATIONS
19	The Authorsâ€™ Reply. <i>Transplantation</i> , 2020, 104, e244-e244.	1.0	0
20	Hepatic Fatâ€™ Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs. <i>Hepatology</i> , 2020, 72, 1912-1923.	7.3	48
21	Reply to: Correspondence on â€œHigh rates of 30-day mortality in patients with cirrhosis and COVID-19â€. <i>Journal of Hepatology</i> , 2020, 73, 1570-1571.	3.7	10
22	Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis. <i>Liver Cancer</i> , 2020, 9, 744-755.	7.7	15
23	Management of hepatocellular carcinoma in the time of COVID-19. <i>Annals of Oncology</i> , 2020, 31, 1084-1085.	1.2	33
24	Pulmonary Resection for Metastasis of Hepatocellular Carcinoma Recurring After Liver Transplant: An Italian Multicenter Experience. <i>Frontiers in Oncology</i> , 2020, 10, 381.	2.8	7
25	High rates of 30-day mortality in patients with cirrhosis and COVID-19. <i>Journal of Hepatology</i> , 2020, 73, 1063-1071.	3.7	279
26	International and multicenter realâ€world study of sorafenibâ€treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020, 40, 1467-1476.	3.9	15
27	Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 947-956.	10.7	166
28	The combination of PIVKAâ€II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on longâ€term oral therapy. <i>Liver International</i> , 2020, 40, 1987-1996.	3.9	44
29	Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. <i>World Journal of Gastroenterology</i> , 2020, 26, 1888-1900.	3.3	20
30	SAT-130-Incidence and outcome of portal vein thrombosis in 817 HBV and HCV compensated cirrhotic patients under antiviral treatment: a single center longitudinal study. <i>Journal of Hepatology</i> , 2019, 70, e687-e688.	3.7	2
31	Minimal increases of serum alphaâ€fetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under longâ€term oral therapy. <i>Liver International</i> , 2019, 39, 1964-1974.	3.9	11
32	ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. <i>Cancers</i> , 2019, 11, 1023.	3.7	23
33	Biliary Stones After Brain Dead Liver Transplantation Today: Rates, Risk Factors, Treatments, and Outcomes. <i>Transplantation Proceedings</i> , 2019, 51, 1939-1945.	0.6	2
34	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 3176-3184.	4.7	60
35	Focus on Very Late Hepatocellular Carcinoma Recurring After Liver Transplantation: A Case Report and Literature Review. <i>Transplantation Proceedings</i> , 2019, 51, 2998-3000.	0.6	2
36	FRI-376-Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: Safety and survival. <i>Journal of Hepatology</i> , 2019, 70, e560-e561.	3.7	1

#	ARTICLE	IF	CITATIONS
37	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , 2019, 11, 1689.	3.7	44
38	TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1233-1236.	2.0	10
39	Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 603-610.	2.4	12
40	AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2019, 51, e38.	0.9	0
41	Incidence and outcome of portal vein thrombosis in 817 HBV and HCV cirrhotic patients under antiviral treatment: a single center longitudinal study. <i>Digestive and Liver Disease</i> , 2019, 51, e10.	0.9	0
42	Safety and effectiveness of Regorafenib in recurrent HCC after liver transplantation and progression on Sorafenib: a real-life multicentre study. <i>Digestive and Liver Disease</i> , 2019, 51, e12.	0.9	1
43	Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: safety and survival. <i>Digestive and Liver Disease</i> , 2019, 51, e35.	0.9	0
44	Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance. <i>Annals of Hepatology</i> , 2019, 18, 318-324.	1.5	4
45	Vortex-core properties and vortex-lattice transformation in FeSe. <i>Physical Review B</i> , 2019, 99, .	3.2	15
46	Clinical but not genetic variables predict the development of hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct acting antivirals: a 3-year study in 509 patients. <i>Digestive and Liver Disease</i> , 2019, 51, e67.	0.9	1
47	The development of hepatocellular carcinoma is not predicted by genetic variants in caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 10 years. <i>Digestive and Liver Disease</i> , 2019, 51, e56.	0.9	0
48	FRI-474-AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, e607.	3.7	0
49	Imaging of combined hepatocellular-choleangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2019, 7, 69-77.	3.8	31
50	Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1183-1191.e7.	4.4	79
51	Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: A single-center prospective 3-year study. <i>Digestive and Liver Disease</i> , 2018, 50, 36.	0.9	1
52	Outbreak of Acute Hepatitis A involving young men in Lombardy region, Italy: Risk factors, clinical and virological characteristics. <i>Digestive and Liver Disease</i> , 2018, 50, 5.	0.9	0
53	Excellent 5-years survival for HBV cirrhotic patients developing a hepatocellular carcinoma during long-term analogs treatment. <i>Digestive and Liver Disease</i> , 2018, 50, 11.	0.9	0
54	Sarcopenia predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>Digestive and Liver Disease</i> , 2018, 50, 14.	0.9	0

#	ARTICLE	IF	CITATIONS
55	Predictors of hepatocellular recurrence after liver transplant in Hepatitis C patients: A ten-years single center cohort. <i>Digestive and Liver Disease</i> , 2018, 50, 54.	0.9	0
56	High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1089-1090.	1.9	6
57	Evolution of Metastable Defects and Its Effect on the Electronic Properties of MoS2 Films. <i>Scientific Reports</i> , 2018, 8, 6724.	3.3	40
58	Multimodal and sequential treatment for hepatocellular carcinoma: How "real-life" complies with international recommendations. <i>Digestive and Liver Disease</i> , 2018, 50, 45.	0.9	0
59	Changes of AFP and PIVKA-II levels during DAA treatment and their predictive value for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment. <i>Digestive and Liver Disease</i> , 2018, 50, 49.	0.9	0
60	Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: Safety and survival. <i>Digestive and Liver Disease</i> , 2018, 50, 49.	0.9	2
61	Baseline clinical features but not TLL1 variants predicts HCC onset in Caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years. <i>Digestive and Liver Disease</i> , 2018, 50, 51.	0.9	0
62	Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter retrospective study of 1,006 nodules. <i>Journal of Hepatology</i> , 2018, 68, 485-492.	3.7	195
63	Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Annals of Hepatology</i> , 2018, 17, 110-118.	1.5	20
64	Severe cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subject. <i>Aids</i> , 2018, 32, 1727-1729.	2.2	2
65	Liver transplant for hepatocellular carcinoma: A heavyweight therapeutic option in need of a new policy on liver graft allocation. <i>Digestive and Liver Disease</i> , 2018, 50, 1351-1352.	0.9	1
66	Liver Transplantations and Brain Dead Donors With Alcohol Abuse. <i>Transplantation Proceedings</i> , 2018, 50, 3105-3110.	0.6	1
67	Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. <i>United European Gastroenterology Journal</i> , 2018, 6, 1039-1048.	3.8	54
68	HCV treatment with DAA in patients listed for liver transplant does not result in an increased risk of HCC recurrence post-liver transplant. <i>Journal of Hepatology</i> , 2018, 68, S117-S118.	3.7	0
69	Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. <i>Liver International</i> , 2018, 38, 1624-1634.	3.9	25
70	Clinical and genetic predictors of HCC occurring in caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years. <i>Journal of Hepatology</i> , 2018, 68, S521-S522.	3.7	0
71	TLL1 variants do not predict the development of de-novo hepatocellular carcinoma in HCV cirrhotics treated with IFN-free DAA-based regimens. <i>Journal of Hepatology</i> , 2018, 68, S527.	3.7	0
72	Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 431-439.	3.7	7

#	ARTICLE	IF	CITATIONS
73	Outbreak of acute hepatitis A involving young men in Lombardy Region, Italy: risk factors, clinical and virological characteristics. <i>Journal of Hepatology</i> , 2018, 68, S33.	3.7	1
74	Multimodal and sequential treatment for hepatocellular carcinoma: how "real-life" complies with international recommendations. <i>Journal of Hepatology</i> , 2018, 68, S203.	3.7	0
75	The long-term risk and outcome of non-neoplastic portal vein thrombosis developing in compensated caucasian HBV cirrhotics treated with Tenofovir or Entecavir. <i>Journal of Hepatology</i> , 2018, 68, S521.	3.7	0
76	Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: a single-center prospective 3 year study. <i>Journal of Hepatology</i> , 2018, 68, S529.	3.7	3
77	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1105-1114.	0.9	41
78	Metastable defects in monolayer and few-layer films of MoS ₂ . <i>AIP Conference Proceedings</i> , 2018, , .	0.4	1
79	Sarcopenia predicts survival in patients with advanced hepatocellular carcinoma treated with Sorafenib. <i>Journal of Hepatology</i> , 2018, 68, S207-S208.	3.7	0
80	Uncommon extrahepatic metastases from hepatocellular carcinoma. <i>Hepatology</i> , 2017, 66, 986-988.	7.3	0
81	Serum markers for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment. <i>Digestive and Liver Disease</i> , 2017, 49, e47.	0.9	0
82	Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. <i>Liver International</i> , 2017, 37, 1526-1534.	3.9	34
83	Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. <i>Digestive and Liver Disease</i> , 2017, 49, e19.	0.9	1
84	Minimal increases of alpha-fetoprotein strongly predict HCC development in caucasian compensated HBV cirrhotics treated by entecavir or tenofovir: A 7-year longitudinal cohort study in 225 patients. <i>Digestive and Liver Disease</i> , 2017, 49, e28.	0.9	0
85	Minimal increases of alpha-fetoprotein above the normal value strongly predict HCC development in compensated Caucasian HBV cirrhotics treated by entecavir or tenofovir: a 7-year longitudinal cohort study in 225 patients. <i>Journal of Hepatology</i> , 2017, 66, S689-S690.	3.7	0
86	Serum Markers for early diagnosis of hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virological response to direct-acting antivirals treatment. <i>Journal of Hepatology</i> , 2017, 66, S209-S210.	3.7	0
87	Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence. <i>Journal of Hepatology</i> , 2017, 67, 1355-1356.	3.7	3
88	Anisotropic Superconducting Gaps and Boson Mode in FeSe 1 ^x S _x Single Crystals. <i>Journal of Superconductivity and Novel Magnetism</i> , 2017, 30, 763-768.	1.8	2
89	Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15666-e15666.	1.6	3
90	Doppler-scanning tunneling microscopy current imaging in superconductor-ferromagnet hybrids. <i>Applied Physics Letters</i> , 2016, 108, .	3.3	5

#	ARTICLE	IF	CITATIONS
91	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. <i>Cancer Cell</i> , 2016, 30, 879-890.	16.8	172
92	Observation of superconducting vortex clusters in S/F hybrids. <i>Scientific Reports</i> , 2016, 6, 38557.	3.3	19
93	Hepatocellular carcinoma developing in European patients with prolonged HBV suppression: Biological and clinical features, and outcome. <i>Digestive and Liver Disease</i> , 2016, 48, e48-e49.	0.9	0
94	The role of serum alphafetoprotein determination in HCV-cirrhosis after antiviral treatment. <i>Digestive and Liver Disease</i> , 2016, 48, e54.	0.9	0
95	ENOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS Study. <i>Digestive and Liver Disease</i> , 2016, 48, e23.	0.9	1
96	Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. <i>Digestive and Liver Disease</i> , 2016, 48, e26.	0.9	0
97	Increased plasma levels of Von Willebrand factor (VWF) and Factor VIII (FVIII) during acute bacterial infection drive a pro-hemostatic imbalance and herald severe outcome in cirrhosis. <i>Digestive and Liver Disease</i> , 2016, 48, e13.	0.9	0
98	Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. <i>Journal of Hepatology</i> , 2016, 64, 1217-1223.	3.7	104
99	Accuracy of the Radiological Diagnosis of Hepatocellular Carcinoma outside the Periodic Surveillance with Ultrasound. <i>Journal of Hepatology</i> , 2016, 64, S335.	3.7	0
100	Prognostic Validation of Proposed BCLC-B Substaging System in Hepatocellular Carcinoma Patients Treated by Transarterial Chemoembolization. <i>Journal of Hepatology</i> , 2016, 64, S333.	3.7	0
101	Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. <i>Liver International</i> , 2016, 36, 166-176.	3.9	19
102	Increased Plasma Levels of Von Willebrand Factor and Factor VIII (FVIII) During Acute Bacterial Infection Drive a Pro-Hemostatic Imbalance and Herald Severe Outcome in Cirrhosis. <i>Journal of Hepatology</i> , 2016, 64, S290-S291.	3.7	0
103	Multimodality Treatment of Hepatocellular Carcinoma: How Field Practice Complies with International Recommendations. <i>Journal of Hepatology</i> , 2016, 64, S699.	3.7	0
104	Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>United European Gastroenterology Journal</i> , 2016, 4, 363-370.	3.8	16
105	Survival in patients with hepatocellular carcinoma and portal vein thrombosis. <i>Digestive and Liver Disease</i> , 2016, 48, e63.	0.9	0
106	A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. <i>Gut</i> , 2016, 65, 1754-1764.	12.1	108
107	Risk of hepatocellular carcinoma in relation to ABO blood type. <i>Digestive and Liver Disease</i> , 2016, 48, 94-96.	0.9	13
108	<i>eNOS</i> polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. <i>Oncotarget</i> , 2016, 7, 27988-27999.	1.8	30

#	ARTICLE	IF	CITATIONS
109	P0206 : Prevention of bleeding following invasive procedures in cirrhotic patients: A single center experience. Journal of Hepatology, 2015, 62, S383.	3.7	0
110	Evolution of the superconducting properties in S_xFeSe . Physical Review B, 2015, 92, .	3.2	35
111	Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma. Liver International, 2015, 35, 2187-2193.	3.9	2
112	Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan status in patients with a small hepatocellular carcinoma. Liver Transplantation, 2015, 21, 1259-1269.	2.4	35
113	Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging. Digestive Diseases, 2015, 33, 735-744.	1.9	19
114	Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology, 2015, 62, 784-791.	7.3	110
115	Low-temperature scanning tunneling microscopy and spectroscopy measurements of ultrathin Pb films. Superconductor Science and Technology, 2015, 28, 045003.	3.5	5
116	Emergence of coherence in the charge-density wave state of 2H-NbSe2. Nature Communications, 2015, 6, 6313.	12.8	123
117	Prevention of bleeding following invasive procedures in cirrhotic patients: A single center experience. Digestive and Liver Disease, 2015, 47, e10.	0.9	0
118	O071 : Telomerase reverse transcriptase mutations are associated with hepatocellular carcinoma in nash. Journal of Hepatology, 2015, 62, S226.	3.7	1
119	A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene. Journal of Hepatology, 2015, 63, 1323-1333.	3.7	22
120	The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. Journal of Hepatology, 2015, 63, 1118-1125.	3.7	74
121	Influence of Domain Width on Vortex Nucleation in Superconductor/Ferromagnet Hybrid Structures. Journal of Superconductivity and Novel Magnetism, 2015, 28, 1107-1110.	1.8	6
122	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut, 2015, 64, 1296-1302.	12.1	70
123	Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. World Journal of Hepatology, 2015, 7, 2053.	2.0	12
124	Vortex-antivortex coexistence in Nb-based superconductor/ferromagnet heterostructures. Physical Review B, 2014, 89, .	3.2	23
125	Influence of topological edge states on the properties of $Al_xBi_{1-x}Sb$ Josephson devices. Physical Review B, 2014, 89, .	3.2	81
126	P965 PERSONALIZED THERAPY WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2014, 60, S397.	3.7	0

#	ARTICLE	IF	CITATIONS
127	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE study. International Journal of Cancer, 2014, 135, 1247-1256.	5.1	109
128	P586 APPEARANCE OF COMBINED HEPATOCELLULAR CHOLANGIOCARCINOMA IN CIRRHOSIS AT CONTRAST ENHANCED IMAGING TECHNIQUES. Journal of Hepatology, 2014, 60, S265.	3.7	0
129	Appearance of combined hepatocellular cholangiocarcinoma in cirrhosis at contrast enhanced imaging techniques. Digestive and Liver Disease, 2014, 46, e17.	0.9	0
130	Magnetic pinning in a superconducting film by a ferromagnetic layer with stripe domains. Superconductor Science and Technology, 2014, 27, 125002.	3.5	4
131	Visualizing domain wall and reverse domain superconductivity. Nature Communications, 2014, 5, 4766.	12.8	28
132	Role of antiviral treatment for HCC prevention. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 771-781.	2.4	31
133	First-line treatment of 90 consecutive HCC with drug eluting beads chemoembolization (DEB-TACE). Digestive and Liver Disease, 2014, 46, e64.	0.9	0
134	O123 POST SORAFENIB SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: THE ROLE OF TUMOR PROGRESSION AND LIVER IMPAIRMENT. Journal of Hepatology, 2014, 60, S51.	3.7	0
135	Post sorafenib survival in patients with advanced hepatocellular carcinoma: The role of tumor progression and liver impairment. Digestive and Liver Disease, 2014, 46, e35-e36.	0.9	0
136	P1059 PORTAL HYPERTENSION BUT NOT HCC RISK IS ATTENUATED IN COMPENSATED CIRRHOTICS FOLLOWING 10 YEARS OF TREATMENT WITH NUCLEOS(T)IDE ANALOGS. Journal of Hepatology, 2014, 60, S429-S430.	3.7	2
137	Portal hypertension but not HCC risk is attenuated in compensated cirrhotics following 10 years of treatment with nucleos(t)ide analogs. Digestive and Liver Disease, 2014, 46, e50.	0.9	0
138	Prognostic Gene Expression Signature for Patients With Hepatitis C-Related Early-Stage Cirrhosis. Gastroenterology, 2013, 144, 1024-1030.	1.3	195
139	Magnetization properties and vortex phase diagram of $Cu_xTi_{1-x}Se$ single crystals. Physical Review B, 2013, 88, 014407.	3.2	11
140	Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. Journal of Hepatology, 2013, 58, 1188-1193.	3.7	110
141	259 DETERMINANTS OF BLEEDING FROM ESOPHAGEAL VARICES IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB. Journal of Hepatology, 2013, 58, S110.	3.7	0
142	Reply to: "Non-invasive diagnosis of small nodules in cirrhosis". Journal of Hepatology, 2013, 59, 1361-1362.	3.7	0
143	HBV Infection and Hepatocellular Carcinoma. Clinics in Liver Disease, 2013, 17, 375-397.	2.1	34
144	722 LIVER STIFFNESS AND HEPATOCELLULAR CARCINOMA: IS IT REALLY USEFUL?. Journal of Hepatology, 2013, 58, S293.	3.7	0

#	ARTICLE	IF	CITATIONS
145	Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis. <i>Digestive and Liver Disease</i> , 2013, 45, 43-49.	0.9	23
146	Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. <i>Liver International</i> , 2013, 33, 771-779.	3.9	91
147	Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 1046-1054.	7.3	89
148	PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e75982.	2.5	42
149	Vortex Confinement in Planar Superconductor/Ferromagnet Hybrid Structures. <i>IEEE Transactions on Magnetics</i> , 2012, 48, 3275-3279.	2.1	7
150	Evolution of the charge density wave state in Cu_xTiSe_2 . <i>Physical Review B</i> , 2012, 85, .	3.2	34
151	716 PROGNOSTIC GENE-EXPRESSION SIGNATURE FOR HEPATITIS C-RELATED EARLY-STAGE LIVER CIRRHOSIS. <i>Journal of Hepatology</i> , 2012, 56, S283.	3.7	0
152	718 CONTRAST-ENHANCED CT SCAN DIFFERENTIATES HEPATOCELLULAR CARCINOMA AND INTRAHEPATIC CHOLANGIOCARCINOMA IN CIRRHOSIS. <i>Journal of Hepatology</i> , 2012, 56, S283-S284.	3.7	0
153	746 PROSPECTIVE VALIDATION OF 2010 AASLD GUIDELINE FOR THE DIAGNOSIS OF 1-2 CM HCC IN CIRRHOTIC PATIENTS. <i>Journal of Hepatology</i> , 2012, 56, S293-S294.	3.7	0
154	Visualizing Vortex Dynamics in Py/Nb Thin Film Hybrids by Low Temperature Magnetic Force Microscopy. <i>Journal of Superconductivity and Novel Magnetism</i> , 2012, 25, 2167-2171.	1.8	5
155	1008 SUSTAINED VIROLOGIC RESPONSE TO INTERFERON PREVENTS THE LETHAL CONSEQUENCE OF CLINICAL DECOMPENSATION IN PATIENTS WHO DEVELOP A HEPATOCELLULAR CARCINOMA POST ANTIVIRAL-TREATMENT. <i>Journal of Hepatology</i> , 2012, 56, S394.	3.7	0
156	Evidence of vortex jamming in Abrikosov vortex flux flow regime. <i>Physical Review B</i> , 2012, 86, .	3.2	18
157	Benign Liver Tumors. , 2012, , 1045-1060.		0
158	Reply.. <i>Hepatology</i> , 2012, 55, 1305-1306.	7.3	0
159	Re: Indeterminate 1-2 cm nodules found on hepatocellular carcinoma surveillance: Biopsy for all, some, or none?. <i>Hepatology</i> , 2012, 55, 651-651.	7.3	0
160	HBV-related HCC, clinical issues and therapy. <i>Digestive and Liver Disease</i> , 2011, 43, S32-S39.	0.9	14
161	OC-1 Prospective Italian multicenter field-practice study with sorafenib for advanced hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2011, 43, S65.	0.9	0
162	F-35 Nucleos(t)ide analogues can be safely discontinued in chronic hepatitis B patients achieving HBsAg seroclearance. <i>Digestive and Liver Disease</i> , 2011, 43, S103.	0.9	0

#	ARTICLE	IF	CITATIONS
163	Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. <i>Digestive and Liver Disease</i> , 2011, 43, 875-80.	0.9	23
164	The spectroscopic signature of the Co magnetic state in $\text{Co}_{1-x}\text{NbSe}_2$ superconducting single crystals. <i>Superconductor Science and Technology</i> , 2011, 24, 024010.	3.5	2
165	753 NUCLEOS(T)IDE ANALOGUES CAN BE SAFELY DISCONTINUED IN CHRONIC HEPATITIS B PATIENTS ACHIEVING HBSAG SEROCLEARANCE. <i>Journal of Hepatology</i> , 2011, 54, S302-S303.	3.7	0
166	Anisotropic Superconductivity and Vortex Dynamics in Magnetically Coupled F/S and F/S/F Hybrids. <i>Journal of Superconductivity and Novel Magnetism</i> , 2011, 24, 905-910.	1.8	2
167	Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. <i>Hepatology</i> , 2011, 53, 1549-1557.	7.3	77
168	Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. <i>Hepatology</i> , 2011, 54, 2055-2063.	7.3	321
169	Imaging the spontaneous formation of vortex-antivortex pairs in planar superconductor/ferromagnet hybrid structures. <i>Physical Review B</i> , 2011, 84, .	3.2	49
170	Dimensionality crossover in vortex dynamics of magnetically coupled F/F hybrids. <i>Superconductor Science and Technology</i> , 2011, 24, 024012.	3.5	0
171	Diagnosis and Stratification of Hepatocellular Carcinoma. , 2011, , 127-134.		0
172	Extended X-ray Absorption Fine Structure spectroscopy in $\text{Co}_{0.013}\text{NbSe}_2$. <i>Journal of Physics: Conference Series</i> , 2010, 200, 012224.	0.4	4
173	Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 180-184.	1.6	47
174	The local effect of magnetic impurities on superconductivity in $\text{Co}_{1-x}\text{NbSe}_2$ and Mn_xNbSe_2 single crystals. <i>Journal of Physics Condensed Matter</i> , 2010, 22, 015501.	1.8	14
175	Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation. <i>Hepatology</i> , 2010, 52, 1723-1730.	7.3	67
176	Giant conductance anisotropy in magnetically coupled Ferromagnet-Superconductor-Ferromagnet structures. <i>Applied Physics Letters</i> , 2010, 96, 092513.	3.3	7
177	Anisotropic transport properties in tilted-dc-axis MgB_2 thin films. <i>Superconductor Science and Technology</i> , 2010, 23, 025012.	3.5	3
178	The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. <i>Gut</i> , 2010, 59, 638-644.	12.1	358
179	Sorafenib-Induced Destructive Thyroiditis. <i>Thyroid</i> , 2010, 20, 1043-1044.	4.5	15
180	CS.2.4 CONTRAST IMAGING TECHNIQUES CORRELATE WITH TUMOR GRADING IN THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS UNDER SURVEILLANCE. <i>Digestive and Liver Disease</i> , 2010, 42, S65.	0.9	0

#	ARTICLE	IF	CITATIONS
181	OC.03.6 FIELD PRACTICE WITH SORAFENIB IN ADVANCED HCC: EFFECTIVENESS CONFIRMED, TOLERABILITY REDUCED BUT USUALLY MANAGEABLE, COMPARED TO REGISTRATION TRIALS. <i>Digestive and Liver Disease</i> , 2010, 42, S77.	0.9	0
182	P.132 CHEMOEMBOLIZATION WITH EPIRUBICIN DRUG ELUTING BEADS TO TREAT EARLY AND INTERMEDIATE HEPATOCELLULAR CARCINOMA. <i>Digestive and Liver Disease</i> , 2010, 42, S149-S150.	0.9	0
183	P.140 NATURAL HISTORY AND MULTIMODALITY TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA PROSPECTIVELY DETECTED IN CIRRHOTIC PATIENTS UNDER SURVEILLANCE. <i>Digestive and Liver Disease</i> , 2010, 42, S152.	0.9	0
184	P.142 THE NATURAL HISTORY OF HEPATIC MACROREGENERATIVE NODULES DEVELOPING IN CIRRHOTIC PATIENTS DURING SURVEILLANCE WITH ULTRASOUND (US). <i>Digestive and Liver Disease</i> , 2010, 42, S153.	0.9	0
185	35 THE NATURAL HISTORY OF HEPATIC MACROREGENERATIVE NODULES DEVELOPING IN CIRRHOTIC PATIENTS DURING SURVEILLANCE WITH ULTRASOUND (US). <i>Digestive and Liver Disease</i> , 2010, 42, S14.	0.9	0
186	T.N.21 DIAGNOSTIC YIELD AND STANDARDIZATION OF FINE NEEDLE BIOPSY IN THE CHARACTERIZATION OF LIVER NODULES IN CIRRHOTIC PATIENTS. <i>Digestive and Liver Disease</i> , 2010, 42, S22.	0.9	0
187	T.N.22 CONTRAST IMAGING TECHNIQUES CORRELATE WITH TUMOR GRADING IN THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS UNDER SURVEILLANCE. <i>Digestive and Liver Disease</i> , 2010, 42, S22-S23.	0.9	0
188	F.N.20 NATURAL HISTORY AND MULTIMODALITY TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA PROSPECTIVELY DETECTED IN CIRRHOTIC PATIENTS UNDER SURVEILLANCE. <i>Digestive and Liver Disease</i> , 2010, 42, S40.	0.9	0
189	F.N.22 FIELD PRACTICE WITH SORAFENIB IN ADVANCED HCC: EFFECTIVENESS CONFIRMED, TOLERABILITY REDUCED BUT USUALLY MANAGEABLE, COMPARED TO REGISTRATION TRIALS. <i>Digestive and Liver Disease</i> , 2010, 42, S41.	0.9	0
190	194 THE NATURAL HISTORY OF HEPATIC MACROREGENERATIVE NODULES DEVELOPING IN CIRRHOTIC PATIENTS DURING SURVEILLANCE WITH ULTRASOUND. <i>Journal of Hepatology</i> , 2010, 52, S84.	3.7	0
191	229 NATURAL HISTORY AND MULTIMODALITY TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA PROSPECTIVELY DETECTED IN CIRRHOTIC PATIENTS UNDER SURVEILLANCE. <i>Journal of Hepatology</i> , 2010, 52, S97.	3.7	0
192	Diagnostic value of Lens culinaris agglutinin isoform 3 fraction (AFP-L3%) and des-gamma-carboxy prothrombin (DCP) for the diagnosis of hepatocellular carcinoma in cirrhotic patients.. <i>Journal of Clinical Oncology</i> , 2010, 28, 4119-4119.	1.6	2
193	Low diagnostic accuracy of the AASLD radiologic criteria for hepatocellular carcinoma in grade I tumors.. <i>Journal of Clinical Oncology</i> , 2010, 28, e14606-e14606.	1.6	0
194	Diagnostic accuracy and standardization of fine needle biopsy in the characterization of liver nodules in cirrhosis.. <i>Journal of Clinical Oncology</i> , 2010, 28, e14576-e14576.	1.6	0
195	Comparison of field practice to registration trials of sorafenib in advanced HCC for effectiveness and tolerability.. <i>Journal of Clinical Oncology</i> , 2010, 28, e14637-e14637.	1.6	0
196	Natural history and multimodality treatment of early hepatocellular carcinoma prospectively detected in cirrhotic patients under surveillance.. <i>Journal of Clinical Oncology</i> , 2010, 28, e14574-e14574.	1.6	0
197	Chemoembolization with epirubicin drug-eluting beads (DEB-TACE) to treat early and intermediate hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2010, 28, 4141-4141.	1.6	1
198	The natural history of hepatic macroregenerative nodules developing in cirrhotic patients during surveillance with ultrasound.. <i>Journal of Clinical Oncology</i> , 2010, 28, e14631-e14631.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Adjustable Superconducting Anisotropy in Superconductor-Ferromagnet Bilayers. IEEE Transactions on Applied Superconductivity, 2009, 19, 3471-3474.	1.7	5
200	Transverse instabilities of multiple vortex chains in magnetically coupled bilayers. Physical Review B, 2009, 80, .	3.2	38
201	The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. Journal of Hepatology, 2009, 50, 746-754.	3.7	280
202	Transarterial embolization with microspheres in the treatment of monofocal HCC. Digestive and Liver Disease, 2009, 41, 143-149.	0.9	6
203	794 PROSPECTIVE STUDY OF DYSPLASTIC NODULES IN CIRRHOSIS: CORRELATION WITH CT VASCULAR PATTERN, HISTOLOGY AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2009, 50, S290-S291.	3.7	2
204	912 PROGRESSIVE DECLINE OF HBsAg TITERS IN LONG- TERM VIROLOGICAL RESPONDERS TO NUCLEOS(T)IDE ANALOGUE THERAPY FOR CHRONIC HEPATITIS B. Journal of Hepatology, 2009, 50, S331.	3.7	1
205	916 ENTECAVIR IS AN EFFECTIVE TREATMENT FOR NUC-NAIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: 48-WEEK DATA FROM A LARGE MULTICENTER COHORT STUDY. Journal of Hepatology, 2009, 50, S333.	3.7	0
206	930 HIGH RISK OF RENAL IMPAIRMENT DURING LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY IN PATIENTS WITH LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B. Journal of Hepatology, 2009, 50, S338-S339.	3.7	8
207	Adjustable superconducting anisotropy in MoGe-Permalloy hybrids. Journal of Physics: Conference Series, 2009, 150, 052095.	0.4	3
208	STM studies of Co _x NbSe ₂ and Mn _x NbSe ₂ . Journal of Physics: Conference Series, 2009, 150, 052073.	0.4	5
209	The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. Antiviral Therapy, 2009, 14, 789-796.	1.0	15
210	PA.102 VERY EARLY ADD-ON ADEFOVIR THERAPY IN PATIENTS WITH SUB-OPTIMAL VIROLOGICAL RESPONSE TO LAMIVUDINE. Digestive and Liver Disease, 2008, 40, S112.	0.9	0
211	PA.103 LOW RISK OF HEPATITIS B REACTIVATION IN PATIENTS WITH CHRONIC HEPATITIS C AND CONCURRENT INACTIVE HEPATITIS B INFECTION TREATED WITH INTERFERON AND RIBAVIRIN. Digestive and Liver Disease, 2008, 40, S112.	0.9	0
212	Prospective validation of AASLD guidelines for the early diagnosis of hepatocellular carcinoma in cirrhotic patients. Digestive and Liver Disease, 2008, 40, A22-A23.	0.9	1
213	389 LOW RISK OF HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION: A 3-YEAR FOLLOW-UP STUDY IN 78 PATIENTS WITH CHRONIC HEPATITIS B. Journal of Hepatology, 2008, 48, S151.	3.7	1
214	696 ADD ON ADEFOVIR PREVENTS THE EMERGENCE OF ADV RESISTANCE IN LAMIVUDINE-RESISTANT PATIENTS: A 4-YEAR STUDY. Journal of Hepatology, 2008, 48, S259.	3.7	7
215	Superconductor/ferromagnet bilayers: Influence of magnetic domain structure on vortex dynamics. Physical Review B, 2008, 77, .	3.2	37
216	Guiding superconducting vortices with magnetic domain walls. Physical Review B, 2008, 77, .	3.2	81

#	ARTICLE	IF	CITATIONS
217	Tunable transport in magnetically coupled MoGe/Permalloy hybrids. Applied Physics Letters, 2008, 93, .	3.3	33
218	Effect of magnetic impurities on the vortex lattice properties in $NbSe_2$ crystals. Physical Review B, 2008, 78, .	3.2	49
219	Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients. Gastroenterology, 2007, 133, 1445-1451.	1.3	290
220	The Role of Hepatic Venous Pressure Gradient in Hepatitis C Virus Compensated Cirrhosis. Gastroenterology, 2007, 133, 2076.	1.3	0
221	Prospective evaluation of staging systems for hepatocellular carcinoma detected during surveillance of cirrhotic patients. Digestive and Liver Disease, 2007, 39, A39.	0.9	0
222	Hepatitis C virus genotype 1b, cirrhosis, and risk of hepatocellular carcinoma. Hepatology, 2007, 47, 357-357.	7.3	2
223	Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. Journal of Viral Hepatitis, 2007, 14, 133-139.	2.0	47
224	69 Local circulation of VEGF is involved in collateral vessels development in cirrhotic patients with portal hypertension. Journal of Hepatology, 2006, 44, S31.	3.7	0
225	85 Five years of sequential LAM TO LAM+ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma. Journal of Hepatology, 2006, 44, S38.	3.7	8
226	STM Observation of Vortex Lattice Transitions in Superconducting Single Crystals with Periodic Pinning Arrays. AIP Conference Proceedings, 2006, , .	0.4	0
227	Direct observation of vortex lattice transitions in mesoscopic superconducting single crystals using STM. Physica C: Superconductivity and Its Applications, 2006, 437-438, 127-131.	1.2	1
228	Switching of magnetic domains in Permalloy microstructures using two-dimensional electron gas. Applied Physics Letters, 2006, 89, 182513.	3.3	1
229	Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology, 2005, 42, 1414-1419.	7.3	270
230	Characterization of off-axis MgB2 epitaxial thin films for planar junctions. Applied Physics Letters, 2005, 87, 242506.	3.3	14
231	Effect of disorder in MgB2 thin films. Physical Review B, 2005, 71, .	3.2	40
232	Direct Observation of Geometrical Phase Transitions in Mesoscopic Superconductors by Scanning Tunneling Microscopy. Physical Review Letters, 2005, 95, 167002.	7.8	92
233	STM tunnelling spectroscopy in MgB2 thin films: the role of band structure in tunnelling spectra. Superconductor Science and Technology, 2004, 17, S106-S111.	3.5	7
234	Assessing Tumor Angiogenesis. Cancer Research, 2004, 64, 4373-4377.	0.9	83

#	ARTICLE	IF	CITATIONS
235	44 The long-term outcome of HBeAg-Negative patients with cirrhosis treated with lamivudine monotherapy: A 5-year prospective cohort study. Journal of Hepatology, 2004, 40, 16-17.	3.7	5
236	251 Increased expression of vascular endothelial growth factor and its receptor in hepatocellular carcinoma and extra-tumoral cirrhotic tissues. Journal of Hepatology, 2004, 40, 79.	3.7	0
237	448 Rescue treatment with adefovir dipivoxil in lamivudine resistant patients with chronic hepatitis B. Journal of Hepatology, 2004, 40, 132-133.	3.7	5
238	Phase Diagram of Single Crystal MgB ₂ . Journal of Low Temperature Physics, 2003, 131, 1237-1244.	1.4	1
239	The clinical and pathogenetic significance of estrogen receptor α expression in chronic liver diseases and liver carcinoma. Cancer, 2003, 98, 529-534.	4.1	54
240	Hydrogen σ steel interaction: relationship between variations of mechanical properties of AISI 304 steel and hydrogen content. International Journal of Hydrogen Energy, 2003, 28, 881-887.	7.1	3
241	Directional scanning tunneling spectroscopy in MgB ₂ . Physica C: Superconductivity and Its Applications, 2003, 385, 215-220.	1.2	15
242	A prospective study of blood alpha-fetoprotein messenger RNA as a predictor of hepatocellular carcinoma in patients with cirrhosis. Journal of Viral Hepatitis, 2003, 10, 423-426.	2.0	6
243	Momentum-dependent scanning tunneling spectroscopy in MgB ₂ . Physica C: Superconductivity and Its Applications, 2003, 388-389, 141-142.	1.2	3
244	Rescue treatment with adefovir dipivoxil for lamivudine resistant patients pre- and post- liver transplantation. Gastroenterology, 2003, 124, A709-A710.	1.3	0
245	Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection. Journal of Hepatology, 2003, 39, 253-261.	3.7	75
246	Genotypic analysis of YMDD locus of HBV in patients responding to lamivudine monotherapy. Journal of Hepatology, 2003, 38, 180.	3.7	0
247	MgB ₂ : directional tunnelling and two-band superconductivity. Superconductor Science and Technology, 2003, 16, 156-161.	3.5	14
248	STM tunneling spectroscopic studies of YNd _x Ba _{2-x} Cu ₃ O _{7-y} thin films. Physical Review B, 2002, 65, .	3.2	9
249	Two-Band Superconductivity in MgB ₂ . Physical Review Letters, 2002, 89, 187002.	7.8	306
250	Study of hepatitis B virus X protein (HBx) mutants and quantification of HBV-DNA in tumorous and non-tumorous hepatocytes using laser capture microdissection (LCM). Journal of Hepatology, 2002, 36, 84-85.	3.7	0
251	Long-term outcome of hepatitis B in lamivudine-resistant cirrhotic patients. Journal of Hepatology, 2002, 36, 115.	3.7	1
252	Surface impedance of R ₁ (Nd _x Ba _{2-x})Cu ₃ O _{7-y} (R=Nd, Y) thin films. Physica C: Superconductivity and Its Applications, 2002, 372-376, 703-705.	1.2	0

#	ARTICLE	IF	CITATIONS
253	Superconducting properties of YNdBaCuO and NdBaCuO thin films deposited by dc sputtering. IEEE Transactions on Applied Superconductivity, 2001, 11, 3201-3204.	1.7	7
254	Scanning Tunneling Spectroscopy in MgB ₂ . Physical Review Letters, 2001, 86, 4374-4377.	7.8	185
255	Superconducting gap anisotropy of LuNi ₂ B ₂ C thin films from microwave surface impedance measurements. Physical Review B, 2001, 64, .	3.2	14
256	<title>Excimer laser ablation of borocarbide targets</title>. , 2000, , .		0
257	Superconducting properties of LuNi ₂ B ₂ C films and junctions. Physica C: Superconductivity and Its Applications, 2000, 341-348, 757-758.	1.2	6
258	SUPERCONDUCTING PROPERTIES OF LuNi ₂ B ₂ C THIN FILMS. International Journal of Modern Physics B, 2000, 14, 2743-2748.	2.0	1
259	Transport properties of ZrN superconducting films. Physical Review B, 2000, 62, 13915-13918.	3.2	32
260	ON THE ROLE OF Nd/Ba DISORDER ON THE SUPERCONDUCTING PROPERTIES OF Re ₁ (Nd _x Ba _{2-x})Cu ₃ O _{7-δ} (Re=Nd, Y) THIN FILMS. International Journal of Modern Physics B, 2000, 14, 2737-2742.	2.0	0
261	Monitoring serum HBV-DNA during lamivudine therapy by quantitative PCR assay may predict development of YMDD mutants. Gastroenterology, 2000, 118, A1461.	1.3	0
262	A simple and reliable system for in situ deposition of large-area double-sided, superconducting films. Superconductor Science and Technology, 2000, 13, 1441-1446.	3.5	5
263	Single and Double Side YBCO Thin Films for X-Band Microwave Filters and Devices. International Journal of Modern Physics B, 1999, 13, 1333-1337.	2.0	15
264	Properties of ErNi ₂ B ₂ C superconducting thin films. Physica C: Superconductivity and Its Applications, 1999, 312, 1-6.	1.2	5
265	Microwave properties of REâ€“Ni ₂ B ₂ C (RE=Y, Er) superconducting thin films. Physica C: Superconductivity and Its Applications, 1999, 319, 141-149.	1.2	5
266	Synthesis and microwave properties of thin films of the 1:2:2:1 borocarbide superconductors YNiBC and ErNiBC. IEEE Transactions on Applied Superconductivity, 1999, 9, 2394-2397.	1.7	0
267	Superconductivity and Antiferromagnetic Order in ErNi ₂ B ₂ C Thin Films. Journal of Superconductivity and Novel Magnetism, 1998, 11, 707-712.	0.5	2
268	STM investigation of BSCCO 2212 and borocarbide materials. Journal of Physics and Chemistry of Solids, 1998, 59, 2030-2033.	4.0	4
269	Synthesis and STM investigation of rare-earth superconducting borocarbides. Superconductor Science and Technology, 1998, 11, 169-172.	3.5	3
270	Unusual Strong-Coupling Effects in the Tunneling Spectroscopy of Optimally Doped and Overdoped Bi ₂ Sr ₂ CaCu ₂ O _{8+δ} . Physical Review Letters, 1998, 80, 153-156.	7.8	187

#	ARTICLE	IF	CITATIONS
271	Properties of YNi ₂ B ₂ C superconducting thin films. Physical Review B, 1997, 56, 934-939.	3.2	20
272	Scanning Tunneling Microscopy Observation of a Square Abrikosov Lattice in LuNi ₂ B ₂ C. Physical Review Letters, 1997, 78, 4273-4276.	7.8	177
273	Nonlinear microwave properties of Nb ₃ Sn sputtered superconducting films. Journal of Applied Physics, 1997, 82, 1736-1742.	2.5	23
274	Microwave measurements of superconducting Nb ₃ /Sn films by a microstrip resonator technique. IEEE Transactions on Applied Superconductivity, 1997, 7, 1772-1775.	1.7	7
275	The superconducting energy gap and vortex lattice structure in LuNi ₂ B ₂ C. Physica C: Superconductivity and Its Applications, 1997, 282-287, 355-358.	1.2	7
276	Re ⁺ Ni ₂ B ₂ C superconducting borocarbides: <i>in situ</i> growth of thin films, transport and point contact spectroscopy. Journal of Low Temperature Physics, 1997, 107, 527-532.	1.4	3
277	In situ film deposition of superconducting borocarbides. Nuovo Cimento Della Societa Italiana Di Fisica D - Condensed Matter, Atomic, Molecular and Chemical Physics, Biophysics, 1997, 19, 995-1001.	0.4	2
278	In situ growth and superconducting properties of YNi ₂ B ₂ C thin films. Applied Physics Letters, 1996, 69, 118-120.	3.3	35
279	Transport and tunneling measurements in superconducting YNi ₂ B ₂ C. Physica C: Superconductivity and Its Applications, 1995, 251, 379-382.	1.2	13
280	Relation between normal-state and superconductive properties of niobium sputtered films. Physical Review B, 1995, 52, 4473-4476.	3.2	29